Navigation Links
HeartWare Presentation At The Barclays Capital 2012 Global Healthcare Conference To Be Webcast
Date:3/7/2012

FRAMINGHAM, Mass. and SYDNEY, March 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Barclays Capital 2012 Global Healthcare Conference at 11:15 am EDT on Tuesday, March 13, 2012.  The conference is being held March 13-14, 2012 at the Loews Miami Hotel, Florida.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864

 


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Schedules Fourth Quarter Conference Call and Webcast
2. HeartWare and Dualis MedTech Announce Agreement to Develop Fully Implantable Ventricular Assist System
3. HeartWare to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. HeartWare to Present at the 23rd Annual Piper Jaffray Health Care Conference
5. HeartWare to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
6. HeartWare to Present at the Credit Suisse 2011 Healthcare Conference
7. HeartWare International Announces Planned Departure of Chief Financial Officer
8. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
9. HeartWare Announces Presentation of Clinical Data at the 25th European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Lisbon
10. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
11. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... , April 24, 2017 Solentim, the ... announced the addition of a major new product ... Plate Seeding,). The VIPS has been developed for ... well microplates as part of the process to ... a simple and more reliable solution when compared ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Addressing Production Complexities Through Risk Management and Quality by ... ... Market Prospects: Overcoming Production Complexities Through Risk Management and ... current trends in the global biosimilars market, with a ...
(Date:4/20/2017)... , April 20, 2017  AbbVie (NYSE: ... 99 percent (n=145/146) of chronic hepatitis C virus ... 5 or 6 and compensated cirrhosis (Child-Pugh A) ... (SVR 12 ) with its investigational, pan-genotypic regimen ... rates were seen following 12 weeks of G/P ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Journal of Oral Implantology ... have severe consequences to overall dental health, including complications with speech, eating, and overcompensation ... dental implants to replace lost teeth. As the number of tooth replacements increase, it ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... Hackensack, N.J. has been honored by Enterprising Women magazine as one of its ... world’s top women business owners. Winners have demonstrated that they have fast-growth businesses, ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... RawTrition now ... easy way to get nutrients from SUPERFOODS! , RawTrition is taking nutrients ... the cellular level because the body recognizes its raw form (unlike the synthetically made ...
(Date:4/26/2017)... ... 26, 2017 , ... MYOLYN, a medical technology company dedicated ... received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for two ... devices are stationary cycling systems that use MYOLYN’s patent-pending functional electrical stimulation ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, and ... its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in Duchenne ...
Breaking Medicine News(10 mins):